{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:10:32Z","timestamp":1781521832438,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009663","name":"University Health Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cllc.2025.04.001","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T18:07:34Z","timestamp":1744135654000},"page":"492-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8696-456X","authenticated-orcid":false,"given":"Louis","family":"Pinard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash Rao","family":"Ullur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Everest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna Jia","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeevan","family":"Selvaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karmugi","family":"Balaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaleeq","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simren","family":"Chotai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devalben","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Al-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Catherine","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roula","family":"Raptis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian G.","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope A.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-5046","authenticated-orcid":false,"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2025.04.001_bib0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.04.001_bib0002","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK -positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.04.001_bib0003","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK -positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.04.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.27561","article-title":"Hypogonadism related to crizotinib therapy: implications for patient care","volume":"118","author":"Ramalingam","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2025.04.001_bib0005","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cam4.437","article-title":"Complex renal cysts associated with crizotinib treatment","volume":"4","author":"Schnell","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.cllc.2025.04.001_bib0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40644-017-0109-5","article-title":"Crizotinib associated renal cysts [CARCs]: incidence and patterns of evolution","volume":"17","author":"Cameron","year":"2017","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.cllc.2025.04.001_bib0007","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/j.jtho.2019.03.010","article-title":"Development of complex renal cysts during crizotinib treatment and also during alectinib treatment: a possible drug class effect?","volume":"14","author":"Longo","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.04.001_bib0008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clinimag.2020.03.011","article-title":"Development of complex renal cysts: a complication associated with Crizotinib therapy","volume":"65","author":"Chen","year":"2020","journal-title":"Clin Imaging"},{"key":"10.1016\/j.cllc.2025.04.001_bib0009","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1097\/JTO.0000000000000326","article-title":"Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer","volume":"9","author":"Lin","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.04.001_bib0010","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2169\/internalmedicine.8445-16","article-title":"Regression of crizotinib-associated complex cystic lesions after switching to Alectinib","volume":"56","author":"Taima","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.cllc.2025.04.001_bib0011","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1634\/theoncologist.2014-0216","article-title":"Spontaneous regression of crizotinib-associated complex renal cysts during continuous Crizotinib treatment","volume":"19","author":"Klempner","year":"2014","journal-title":"The Oncologist"},{"key":"10.1016\/j.cllc.2025.04.001_bib0012","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.28478","article-title":"Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib: eGFR and Crizotinib","volume":"120","author":"Brosnan","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2025.04.001_bib0013","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jtho.2019.02.015","article-title":"Renal effects of crizotinib in patients with ALK-positive advanced NSCLC","volume":"14","author":"Camidge","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.04.001_bib0014","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s13256-018-1849-y","article-title":"Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature","volume":"12","author":"Ramachandran","year":"2018","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.cllc.2025.04.001_bib0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s13256-022-03532-2","article-title":"Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report","volume":"16","author":"Van Londen","year":"2022","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.cllc.2025.04.001_bib0016","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/1078155220961549","article-title":"Lorlatinib induced proteinuria: A case report","volume":"27","author":"Lee","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.cllc.2025.04.001_bib0017","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.xphs.2017.03.013","article-title":"Inhibitory effect of Crizotinib on creatinine uptake by renal secretory transporter OCT2","volume":"106","author":"Arakawa","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.cllc.2025.04.001_bib0018","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1038\/s41598-018-27672-y","article-title":"Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1","volume":"8","author":"Omote","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2025.04.001_bib0019","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10637-016-0379-y","article-title":"The renal effects of ALK inhibitors","volume":"34","author":"Izzedine","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.cllc.2025.04.001_bib0020","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3747\/co.27.6563","article-title":"Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment","volume":"27","author":"Tse","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cllc.2025.04.001_bib0021","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cllc.2025.04.001_bib0022","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.cllc.2025.04.001_bib0023","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2215\/CJN.0000000000000508","article-title":"Assessment of GFR in patients with cancer: a statement from the American Society of Onco-Nephrology","volume":"19","author":"Kitchlu","year":"2024","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.cllc.2025.04.001_bib0024","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2215\/CJN.0000000000000509","article-title":"Assessment of GFR in patients with cancer part 2: anticancer therapies-perspectives from the American Society of Onco-Nephrology (ASON)","volume":"19","author":"Kitchlu","year":"2024","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.cllc.2025.04.001_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cllc.2022.09.007","article-title":"Real-world treatment sequencing, toxicities, health utilities, and survival outcomes in patients with advanced ALK-rearranged non-small-cell lung cancer","volume":"24","author":"Schmid","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2025.04.001_bib0026","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1470-2045(13)70142-6","article-title":"CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study","volume":"14","author":"Seto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.04.001_bib0027","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2020.10.024","article-title":"Phase 1\/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: results from ASCEND-6","volume":"150","author":"Wu","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2025.04.001_bib0028","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0272-6386(95)90001-2","article-title":"The link between hypertension and nephrosclerosis","volume":"25","author":"Freedman","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cllc.2025.04.001_bib0029","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/ki.1992.241","article-title":"Experimental chronic renal ischemia: morphologic and immunologic studies","volume":"41","author":"Truong","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.cllc.2025.04.001_bib0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/his.13064","article-title":"Drug-induced nephropathies","volume":"70","author":"Paueksakon","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.cllc.2025.04.001_bib0031","first-page":"138","article-title":"Increased tubular creatinine secretion by remnant nephrons-unexplained but informative?","volume":"4","author":"Ellam","year":"2011","journal-title":"NDT Plus"},{"key":"10.1016\/j.cllc.2025.04.001_bib0032","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13293-021-00373-4","article-title":"Acute kidney injury is more common in men than women after accounting for socioeconomic status, ethnicity, alcohol intake and smoking history","volume":"12","author":"Loutradis","year":"2021","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.cllc.2025.04.001_bib0033","first-page":"126","article-title":"The effect of gender on acute kidney injury developing in the intensive care unit","volume":"23","author":"G\u00fczel","year":"2019","journal-title":"Hippokratia"},{"key":"10.1016\/j.cllc.2025.04.001_bib0034","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13054-019-2314-z","article-title":"The aftermath of acute kidney injury: a narrative review of long-term mortality and renal function","volume":"23","author":"Fortrie","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.cllc.2025.04.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omy009","article-title":"Progressive renal insufficiency related to ALK inhibitor, alectinib","volume":"2018","author":"Nagai","year":"2018","journal-title":"Oxf Med Case Rep"},{"key":"10.1016\/j.cllc.2025.04.001_bib0036","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lungcan.2013.08.007","article-title":"Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma","volume":"82","author":"Gastaud","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2025.04.001_bib0037","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/ckj\/sfac062","article-title":"Anaplastic lymphoma kinase inhibitors and their effect on the kidney","volume":"15","author":"Bonilla","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.cllc.2025.04.001_bib0038","first-page":"1634","article-title":"Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate","volume":"9","author":"Camidge","year":"2014","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.cllc.2025.04.001_bib0039","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jtho.2023.09.1444","article-title":"Brief Report: tyrosine kinase inhibitors for lung cancers that inhibit MATE-1 can lead to \u201cfalse\u201d decreases in renal function","volume":"19","author":"Chen","year":"2024","journal-title":"J Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:43:56Z","timestamp":1759351436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1525730425000592"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.04.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}